Hormonal biomarkers remain prognostically relevant within the molecular subgroups in endometrial cancer

• Autoři: VREDEA Stephanie W; JAN Van Weelden Willem; BULTEN Johan; GILKS C Blake; TEERENSTRA Steven; HUVILA Jutta; MATIAS-GUIU Xavier; GIL-MORENO Antonio; ASBERGERJ Jasmin; SWEEGERS Sanne; VAN DER PUTTEN Louis J M; KUESTERS-VANDEVELDE Heidi V N; REIJNEN Casper; COLASI Eva; HAUSNEROVÁ Jitka; WEINBERGER Vít; SNIJDERS Marc P L M; VINKLEROVA Petra; RAVAGGI Antonella; ODICINO Franco; BIGNOTTI Eliana; MCALPINE Jessica N; KRUITWAGEN Roy; PIJNENBORGA Johanna M A
• Rok publikování: 2025
• Druh: Článek v odborném periodiku
• Časopis / Zdroj: Gynecologic oncology
• Fakulta / Pracoviště MU: Lékařská fakulta
• www: https://www.sciencedirect.com/science/article/pii/S0090825824011855?via%3Dihub
• Doi: http://dx.doi.org/10.1016/j.ygyno.2024.10.028
• Klíčová slova: Endometrial carcinoma; Prognosis; Biomarkers; Pathology; Molecular classification; Immunohistochemical
• Popis: Objective. The prognostic relevance of hormonal biomarkers in endometrial cancer (EC) has been wellestablished. A refined three-tiered risk model for estrogen receptor (ER)/progesterone receptor (PR) expression was shown to improve prognostication. This has not been evaluated in relation to the molecular subgroups. This study aimed to evaluate the ER/PR expression within the molecular subgroups in EC. Methods. A retrospective multicenter cohort study was performed and data from the European Network for Individualized Treatment centers and Vancouver, Canada were used. ER/PR immunohistochemical expression was grouped as: ER/PR 0-10 %, 20-80 % or 90-100 %. Molecular subgroups were determined with full nextgeneration sequencing or combined with immunohistochemistry: POLEmut, mismatch repair deficient (MMRd), p53mut and no-specific molecular profile (NSMP). Results. A total of 739 patients were included (median follow-up 5.0 years). Tumors were classified as POLEmut in 9.1 %(N = 67), MMRd in 27.6 %(N = 204), p53mut in 20.8 %(N = 154) and NSMP in 42.5 %(N = 314). Among all molecular subgroups, patients with ER/PR 90-100 % expression revealed the best disease- specific survival (DSS). Within p53mut, PR 90-100 % expression showed a 5-year DSS of 100.0 %. ER expression is prognostic more relevant in MMRd and NSMP tumors while PR expression in p53mut and NSMP tumors. Across all molecular subgroups, PR 0-10 %, p53mut, lympho-vascular space invasion and FIGO stage III-IV remained independently prognostic for reduced DSS Whereas PR 90-100 % and POLEmut remained independently prognostic for improved DSS. Conclusion. We demonstrated that ER/PR expression remain prognostically relevant within the molecular subgroups, and that a three-tiered cutoff refines prognostication. These data support incorporating routine evaluation of ER/PR expression in clinical practice. (c) 2024 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).